sellNotable cluster of 9
Dawn Carter Bir sold $8.5M of RETA
Chief Commercial Officer at REATA PHARMACEUTICALS INC. 96,996 shares at an average of $87.67, traded Mar 6, 2023, filed Mar 8, 2023.
Warning score
60Value
$8.5M
96,996 shares
Holdings after
41,513
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$8.5M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster9 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-017258, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2023 | CConversion Class A common stock | +48,370 | - | - | 96,879 | Mar 8, 2023 |
| Mar 6, 2023 | SOpen-market sale Class A common stock | -40,134 | $89.30 | $3.6M | 56,745 | Mar 8, 2023 |
| Mar 6, 2023 | SOpen-market sale Class A common stock | -14,820 | $90.26 | $1.3M | 41,925 | Mar 8, 2023 |
| Mar 7, 2023 | CConversion Class A common stock | +41,630 | - | - | 83,555 | Mar 8, 2023 |
| Mar 7, 2023 | SOpen-market sale Class A common stock | -36,049 | $85.08 | $3.1M | 47,506 | Mar 8, 2023 |
| Mar 7, 2023 | SOpen-market sale Class A common stock | -5,793 | $85.90 | $498k | 41,713 | Mar 8, 2023 |
| Mar 7, 2023 | SOpen-market sale Class A common stock | -200 | $86.67 | $17k | 41,513 | Mar 8, 2023 |
| Mar 6, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -48,370 | $0.00 | $0 | 41,630 | Mar 8, 2023 |
| Mar 6, 2023 | MOption exercise Class B common stockderivative | +48,370 | $21.05 | $1.0M | 48,370 | Mar 8, 2023 |
| Mar 6, 2023 | CConversion Class B common stockderivative | -48,370 | - | - | 0 | Mar 8, 2023 |
| Mar 7, 2023 | MOption exercise Employee Stock Option (right to buy)derivative | -41,630 | $0.00 | $0 | 0 | Mar 8, 2023 |
| Mar 7, 2023 | MOption exercise Class B common stockderivative | +41,630 | $21.05 | $876k | 41,630 | Mar 8, 2023 |
| Mar 7, 2023 | CConversion Class B common stockderivative | -41,630 | - | - | 0 | Mar 8, 2023 |
Related signals
Other insiders at REATA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $808k 9,317 shares | -22% | |
| 53Moderate | REATA PHARMACEUTICALS INC | Shamim Ruff director | $481k 5,740 shares | -52% | |
| 50Moderate | REATA PHARMACEUTICALS INC | Andrea Loewen SVP, Global Regulatory Affairs | $1.6M 19,036 shares | -33% | |
| 30Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $14k 165 shares | -1% | |
| 45Moderate | REATA PHARMACEUTICALS INC | Samina Khan SVP, Chief Medical Officer | $331k 3,961 shares | -9% | |
| 37Weak | REATA PHARMACEUTICALS INC | Colin John Meyer Chief Innovation Officer | $53k 621 shares | -1% | |
| 36Weak | REATA PHARMACEUTICALS INC | Michael D Wortley Chief Legal Officer | $35k 414 shares | -1% | |
| 44Moderate | REATA PHARMACEUTICALS INC | Manmeet Singh Soni COO, CFO and President | $53k 622 shares | -1% | |
| 38Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $72k 820 shares | -3% | |
| 42Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $191k 2,166 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.